Format

Send to

Choose Destination
Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Author information

1
Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada. Electronic address: lseymour@ctg.queensu.ca.
2
Ligue Nationale Contre le Cancer Meta-Analysis Platform, Biostatistics and Epidemiology Unit, Gustave Roussy Cancer Campus, Villejuif, France; Inserm U1018, CESP, Université Paris-Saclay, Université Paris-Sud, UVSQ, Villejuif, France.
3
Inserm U1209, Institut Albert Bonniot, Département de Pathologie, CHU Hospital Albert Michallon University Grenoble Alpes, Grenoble, France.
4
Departments of Medical Oncology and Hematology (FAS) and Pathology (M-ST), University Health Network, Princess Margaret Cancer Centre, and the University of Toronto, Toronto, Ontario, Canada.
5
Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France; Universite Paris-sud, Orsay, France.
6
Department of Medicine, University of Minnesota, Minneapolis, MN.
7
SUNY Upstate Medical University, Syracuse, NY.
8
Institut de Cancerologie de l'Ouest, Saint Herblain, France.
9
Catalan Institute of Oncology, Barcelona, Spain.
10
University of New Brunswick, Saint John, New Brunswick, Canada.
11
Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
12
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
13
Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.
14
Ligue Nationale Contre le Cancer Meta-Analysis Platform, Biostatistics and Epidemiology Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Abstract

BACKGROUND:

Complete resection of non-small-cell lung cancer (NSCLC) offers the potential for cure after surgery and adjuvant chemotherapy. Patients may not benefit and may experience severe toxicity. There are no validated molecular tools to allow better patient selection.

MATERIALS AND METHODS:

The LACE-Bio (LACE [Lung Adjuvant Cisplatin Evaluation]) project includes 4 trials (International Adjuvant Lung Cancer Trial [IALT], Adjuvant Navelbine International Trialist Association [ANITA], JBR10, and Cancer and Leukemia Group B (CALGB)-9633). Immunohistochemistry biomarkers shown in one trial to have a prognostic/predictive effect on overall survival were tested.

RESULTS:

The majority of the promising biomarkers could not be validated; the prognostic effect of tumor infiltrating lymphocytes and β-tubulin was confirmed. Potential causes include tissue fixation, storage, the use of tissue microarrays, and varying reagent/antibody batches.

CONCLUSIONS:

Immunohistochemistry assays from single trials may be misleading and require validation before being used for patient selection. LACE-Bio-2 is evaluating potential genomic biomarkers that may allow more precise selection of patients with NSCLC for adjuvant chemotherapy in NSCLC.

KEYWORDS:

Adjuvant chemotherapy; Biomarkers; NSCLC; Predicative; Prognostic

PMID:
30414783
DOI:
10.1016/j.cllc.2018.10.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center